-Reuters
HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Lowers Price Target to $15
HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and lowers the price target from $25 to $15.